Drug intelligence / Profile preview

JY22

Development stage: Preclinical
Lead developer: Jiuyuan Gene Engineering
Modality: Recombinant Proteins and Enzymes
Administration: Local

Overview

JY22 is a recombinant protein-based bone repair drug being developed by Hangzhou Jiuyuan Gene Engineering for the treatment of bone defects. It is a recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) related product, designed to promote bone regeneration. The mechanism of action involves the induction of mesenchymal stem cell differentiation into osteoblasts through the activation of bone morphogenetic protein (BMP) signaling pathways. This osteoinductive property is critical for repairing significant bone voids or defects where natural healing is insufficient. JY22 is currently in the IND-enabling or IND application stage of development.

Other names: rhBMP-2P related proteinrhBMP2P related proteinrhBMP 2P related protein

Targets

BMPR (Bone morphogenetic protein receptor)

Beyond the preview

Go deeper on JY22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY22.

Explore the full profile